创伤性颅脑损伤后hbo介入的时效性分析-timeliness analysis of hbo intervention after traumatic brain injury.docxVIP

Abstrac t IVIVABSTRACTObjective：To investigate the chronergy for Hyperbaric O xygen treatment on Brain Traumatic injury.Methods：We selected 269 cases of traumatic brain injury patients which came from the Department of Rehabilitation of People’s Liberation Army 94 hospital between the April 2013 to December 2014 and all of patients had received conventional drug treatment or conventional drug treatment with hyperbaric oxygen therapy and performed a retrospective analysis. These cases include 112 cases of slight head trauma patients, 88 patients with moderate traumatic brain injury, 67 patients with severe traumatic brain injury. According to these patients whether hyperbaric oxygen therapy had been used in the treatment of traumatic brain injury were divided into 2 groups of hyperbaric oxygen therapy in the treatme nt group and no hyperbaric oxygen therapy group (conventional therapy, hyperbaric oxygen therapy is not involved). According the time hyperbaric oxygen therapy using to these patients can be divided into four groups: A group (less than 15days after the injury), group B (16 ~ 30 days after injury), group C (more than 31 days and 31 days after injury), group D (no hyperbaric oxygen therapy). Hyperbaric oxygen therapy in the treatment group with three courses, the negative control group were not treated with hyperbaric oxygen. Before treatment, patients were scored through GCS. And patients were scored through GOS after HBO treatment. Then we compared the effect of hyperbaric oxygen therapy on each group.Results：Comparison of hyperbaric oxygen therapy group and the negative control group ， the efficiency has significantly different (P 0.05), GOS score after treatment were compared, the difference was statistically significant (P 0.05).A group of patients with GCS score before treatment was 9.72 ± 3.56, BVIVIgroup of patients with GCS score before treatment 9.85 ± 3.24, group C patientsbefore treatment GCS score 9.78 ± 3.72, C group of patients with